Valuation: Novacyt

Market Cap 30.47M 34.85M 28.11M 25.84M 48.96M 3.35B 49.79M 336M 132M 1.64B 131M 128M 5.65B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.43M 37.09M 29.91M 27.5M 52.1M 3.57B 52.99M 357M 140M 1.74B 139M 136M 6.01B EV / Sales 2026 *
1.06x
EV / Sales 2027 * 1.01x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.48%
1 week+6.46%
Current month+6.59%
1 month+2.56%
3 months+13.34%
6 months+3.96%
Current year+7.54%
1 week 0.4
Extreme 0.4025
0.45
1 month 0.38
Extreme 0.3765
0.52
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Date Insider Type Main position Quantity % Market Cap.
03-30Buy

Chairman

15,228 0.0216%
03-30Buy

Chairman

56,732 0.0803%
03-30Buy

Chief Executive Officer

56,438 0.0799%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%+6.46%-10.72%-18.35% 34.7M
+1.67%+0.23%-32.54%-36.36% 626M
+17.70%+46.96%+217.61% - 481M
+7.09%+0.45%-39.22%+29.99% 111M
-5.32%-6.32%+4.71%+66.88% 110M
Average +4.32%+10.81%+27.97%+10.54% 272.37M
Weighted average by Cap. +7.18%+17.61%+58.77%-14.42%

Financials

2026 *2027 *
Net sales 30.52M 34.91M 28.16M 25.88M 49.05M 3.36B 49.88M 336M 132M 1.64B 131M 128M 5.66B 34.86M 39.87M 32.16M 29.56M 56.01M 3.84B 56.97M 384M 151M 1.88B 150M 146M 6.46B
Net income - -
Net Debt 1.96M 2.24M 1.8M 1.66M 3.14M 215M 3.2M 21.54M 8.45M 105M 8.4M 8.22M 363M 4.84M 5.54M 4.47M 4.11M 7.78M 533M 7.91M 53.33M 20.92M 260M 20.8M 20.34M 898M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
15/07/26 €0.4205 +0.48% 425,005
14/07/26 €0.4185 +2.20% 192,433
13/07/26 €0.4095 +1.24% 38,099
10/07/26 €0.4045 -1.10% 59,663
09/07/26 €0.4090 +3.54% 60,807

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock